Infections in Patients with Solid Tumors Undergoing Adoptive Cellular Therapy.

IF 3.6 3区 医学 Q2 HEMATOLOGY
Viswatej Avutu, Jumanah N Algazaq, Kenneth Seier, Rhoena Desir-Camille, Li-Xuan Qin, Olayode Babatunde, Prasad S Adusumilli, Christopher A Klebanoff, Ritesh R Kotecha, Alexander N Shoushtari, Susan Slovin, Allison Betof Warner, Jae H Park, Adam J Schoenfeld, Roisin O'Cearbhaill, Sandra D'Angelo, Susan K Seo
{"title":"Infections in Patients with Solid Tumors Undergoing Adoptive Cellular Therapy.","authors":"Viswatej Avutu, Jumanah N Algazaq, Kenneth Seier, Rhoena Desir-Camille, Li-Xuan Qin, Olayode Babatunde, Prasad S Adusumilli, Christopher A Klebanoff, Ritesh R Kotecha, Alexander N Shoushtari, Susan Slovin, Allison Betof Warner, Jae H Park, Adam J Schoenfeld, Roisin O'Cearbhaill, Sandra D'Angelo, Susan K Seo","doi":"10.1016/j.jtct.2025.02.017","DOIUrl":null,"url":null,"abstract":"<p><p>Adoptive cellular therapy (ACT) is an increasingly widely used treatment approach for malignancy. While infectious complications of ACT have been well described in patients with hematologic malignancies, limited data are available on the epidemiology of infections in patients with solid tumors. The purpose of this study was to describe the epidemiology of infections occurring within the first 180 days in adult patients with solid tumors treated with ACT and to identify risk factors predisposing these patients to infection. Data on 132 adult patients with solid tumors undergoing ACT between August 2014 and November 2021 at Memorial Sloan Kettering Cancer Center were collected. Infections were documented from the day of ACT infusion through day 180 postinfusion. Overall, 28 of 132 patients (21.2%) experienced 33 infections within the first 30 days of ACT, and 17 of 131 surviving patients (13%) were diagnosed with 24 infections between day 31 and day 180. Infection-related mortality was low. The majority of infections were bacterial. While male gender, older age, Eastern Cooperative Oncology Group (ECOG) performance status (PS) at time of ACT infusion, tocilizumab receipt, and cytokine release syndrome treated with tocilizumab were associated with shorter time to first infection on univariable analysis, only ECOG PS and tocilizumab receipt remained independent risk factors in the multivariable analysis. The proportion of patients with solid tumors experiencing early or late infections after ACT was lower compared to that reported among patients with B cell malignancies after chimeric antigen receptor T cell therapy. Most observed infections were primarily bacterial with low infection-related mortality; the incidence of viral and fungal infections was low. Based on the low frequency and timing of infections relative to neutropenia, antibacterial and antifungal prophylaxis are not likely to be beneficial. ECOG PS ≥2 and tocilizumab receipt were identified as significant predictors for infection after ACT, likely signaling an individual's debilitated state that predisposes to infection. Additional work to parse out confounders is needed to better identify risk factors for infection.</p>","PeriodicalId":23283,"journal":{"name":"Transplantation and Cellular Therapy","volume":" ","pages":""},"PeriodicalIF":3.6000,"publicationDate":"2025-02-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Transplantation and Cellular Therapy","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/j.jtct.2025.02.017","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"HEMATOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Adoptive cellular therapy (ACT) is an increasingly widely used treatment approach for malignancy. While infectious complications of ACT have been well described in patients with hematologic malignancies, limited data are available on the epidemiology of infections in patients with solid tumors. The purpose of this study was to describe the epidemiology of infections occurring within the first 180 days in adult patients with solid tumors treated with ACT and to identify risk factors predisposing these patients to infection. Data on 132 adult patients with solid tumors undergoing ACT between August 2014 and November 2021 at Memorial Sloan Kettering Cancer Center were collected. Infections were documented from the day of ACT infusion through day 180 postinfusion. Overall, 28 of 132 patients (21.2%) experienced 33 infections within the first 30 days of ACT, and 17 of 131 surviving patients (13%) were diagnosed with 24 infections between day 31 and day 180. Infection-related mortality was low. The majority of infections were bacterial. While male gender, older age, Eastern Cooperative Oncology Group (ECOG) performance status (PS) at time of ACT infusion, tocilizumab receipt, and cytokine release syndrome treated with tocilizumab were associated with shorter time to first infection on univariable analysis, only ECOG PS and tocilizumab receipt remained independent risk factors in the multivariable analysis. The proportion of patients with solid tumors experiencing early or late infections after ACT was lower compared to that reported among patients with B cell malignancies after chimeric antigen receptor T cell therapy. Most observed infections were primarily bacterial with low infection-related mortality; the incidence of viral and fungal infections was low. Based on the low frequency and timing of infections relative to neutropenia, antibacterial and antifungal prophylaxis are not likely to be beneficial. ECOG PS ≥2 and tocilizumab receipt were identified as significant predictors for infection after ACT, likely signaling an individual's debilitated state that predisposes to infection. Additional work to parse out confounders is needed to better identify risk factors for infection.

接受适应性细胞疗法的实体瘤患者的感染。
背景:过继细胞疗法(ACT)是一种越来越广泛应用于恶性肿瘤的治疗方法。虽然在血液学恶性肿瘤患者中已经很好地描述了ACT的感染性并发症,但关于实体肿瘤患者感染流行病学的数据有限。目的:本研究的目的是描述接受ACT治疗的成年实体瘤患者在头180天内发生感染的流行病学,并确定易使这些患者感染的危险因素。研究设计:收集了2014年8月至2021年11月在纪念斯隆凯特琳癌症中心接受ACT治疗的132名成年实体肿瘤患者的数据。感染记录从ACT输注当天到输注后180天。结果:总体而言,132名患者中有28名(21.2%)在ACT治疗的前30天内经历了33次感染,131名存活患者中有17名(13%)在31天至180天期间被诊断出24次感染。感染相关死亡率较低。大多数感染是细菌感染。单变量分析中,男性、年龄较大、ACT输注时东部肿瘤合作组(ECOG)表现状态(PS)、托珠单抗接受情况和托珠单抗治疗的细胞因子释放综合征(CRS)与首次感染时间较短相关,而在多变量分析中,只有ECOG PS和托珠单抗接受情况仍然是独立的危险因素。结论:与CAR - T细胞治疗后的B细胞恶性肿瘤患者相比,ACT治疗后实体瘤患者出现早期或晚期感染的比例较低。大多数观察到的感染主要是细菌感染,感染相关死亡率低;病毒和真菌感染的发生率较低。基于与中性粒细胞减少症相关的感染的低频率和时间,抗菌和抗真菌预防不太可能有益。ECOG表现状态≥2和接受tocilizumab被认为是ACT后感染的重要预测因素,可能表明个体的衰弱状态易发生感染。为了更好地确定感染的危险因素,需要进行更多的工作来分析混杂因素。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
7.00
自引率
15.60%
发文量
1061
审稿时长
51 days
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信